Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- A New Index Of Emerging Biotech And Pharma Companies
Nov 22, 2008 08:25 PM
- Pharmaceuticals Industry
Nov 21, 2008 04:22 PM
- 11 Stocks To Watch: Some Stocks To Buy For Bounces And Shorts As Usual
Oct 08, 2008 12:28 PM
- Analyst Comments: GOL, Allied Waste, Burlington Northern, Turkcell, Dendreon, American Medical, Wilmington Trust, Silicon Lab, NII Holdings
Aug 15, 2008 02:49 PM
- Mixed Earnings & Data
Aug 13, 2008 10:01 AM
- Analyst Comments: Dendreon, Magellan, Baxter, Regis, Whole Foods
Jul 15, 2008 03:30 PM
- Quiet Day
Jun 11, 2008 11:56 AM
- Biotech to Outperform in Down Market
Apr 21, 2008 06:20 PM
- First Rally Attempt
Apr 15, 2008 10:42 AM
- Observations and Stocks for Friday
Apr 11, 2008 12:50 AM
- Dendreon Reports Third Quarter 2008 Financial Results
Nov 07, 2008 07:30 AM
- Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
Nov 06, 2008 07:31 AM
- Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
Oct 23, 2008 07:31 AM
- Beacon Equity Issues Technical Trade Alerts on Market Movers: DNDN, SPSN, SONS, CEGE, IDEV, ARDM
Oct 07, 2008 09:02 AM
- Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
Oct 06, 2008 08:31 AM
- Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
Oct 06, 2008 07:00 AM
- Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
Sep 17, 2008 07:30 AM
- Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
Aug 29, 2008 07:30 AM
- Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
Aug 14, 2008 07:30 AM
- Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
Aug 13, 2008 07:02 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
DNDN
|
Compare to S&P
|
| YTD |
-21.54 %
|
28.54 %
|
| 4 Weeks |
-0.81 %
|
7.21 %
|
| 12 Weeks |
-13.78 %
|
19.51 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -61.11 %
|
|
EPS Growth in Last Year: -26.09 %
|
|
Sales Growth in Last Quarter: 0.00 %
|
|
Sales Growth in Last Quarter: -76.79 %
|
|
|
